Search

Displaying results 2531 - 2540 of 10000 in total
  1. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein substrates
  2. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    It first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … ], which are derivatives of [vitamin A].

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inducers
  3. Drug

    Eftrenonacog alfa

    go.drugbank.com/drugs/DB11608
    Approved

    episodes caused spontaneously or as a result of accidental or surgical trauma [FDA Label]. … Eftrenonacog alfa acts as a replacement therapy to restore the levels of factor IX and allow normal hemostasis.

  4. Drug

    Phytosphingosine

    go.drugbank.com/drugs/DB14119
    Investigational

    International brands: Biomide PSMixtures: P1P AC Repair Ampoule
  5. Drug

    Caprylyl glycol

    go.drugbank.com/drugs/DB14589
    Investigational

    Mixtures: YOUNGCELLOGY AIOS LV Serum
  6. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262076] Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible … [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.

  7. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

  8. Drug

    Quazepam

    go.drugbank.com/drugs/DB01589
    ApprovedIllicit

    Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inhibitors
  9. Drug

    Mifepristone

    go.drugbank.com/drugs/DB00834
    ApprovedInvestigational

    As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. … Mifepristone is a progestational and glucocorticoid hormone antagonist.

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  10. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm … [A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma